Revelation Biosciences Inc
-0.09 (-5.88%)


Draw Mode:

Volume 151,472
Bid Price 1.45
Ask Price 1.49
News -
Day High 1.528


52 Week Range


Day Low 1.42
Company Name Stock Ticker Symbol Market Type
Revelation Biosciences Inc REVB NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.09 -5.88% 1.44 18:02:17
Open Price Low Price High Price Close Price Prev Close
1.46 1.42 1.528 1.45 1.53
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
991 151,472 $ 1.47 $ 222,689 - 1.27 - 99.40
Last Trade Time Type Quantity Stock Price Currency
17:51:24 1 $ 1.48 USD

Revelation Biosciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 5.14M 3.57M 3.47M $ - $ - -32.41 -0.10
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 1.96M 34.20%

more financials information »

Revelation Biosciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No REVB Message Board. Create One! See More Posts on REVB Message Board See More Message Board Posts

Historical REVB Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.411.551.271.40195,1430.032.13%
1 Month2.102.501.271.84413,474-0.66-31.43%
3 Months6.52411.39251.275.96545,591-5.08-77.93%
6 Months9.313517.5491.2710.981,142,099-7.87-84.54%
1 Year93.4599.401.2727.622,005,460-92.01-98.46%
3 Years293.30341.251.2736.782,145,140-291.86-99.51%
5 Years293.30341.251.2736.782,145,140-291.86-99.51%

Revelation Biosciences Description

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99.